Slide 1: Orion Half-Year Financial Report 1-6/2021
Orion Half-Year Financial Report 1−6/2021
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipated benefits of
Slide 3: Highlights in January-June 2021
Highlights in January-June 2021
Slide 4: Orion's operating profit without milestones at previous year's level
Orion’s operating profit without milestones at previous year’s level Net sales & • Milestones EUR 2 (33) million operating profit • Nubeqa® sales booked by Orion showed strong growth • Specialty Products had a good start for the year despite net sales declined from the strong comparison period • Ani
Slide 5: Key figures 1-6/2021
Key figures 1−6/2021 Net sales Operating profit Operating profit Cash flow per share margin before financial items 524 146 28% 0.53 MEUR (572) MEUR (181) (32%) EUR (0.90) -9% -19% -41% Half-Year Financial Report 1-6/2021 © Orion Corporation 19 July 2021 5
Slide 6: Development of net sales in 1-6/2021 vs. 1-6/2020
Development of net sales in 1-6/2021 vs. 1-6/2020 572 -14 11 -5 5 -5 -7 -1 -32 524 * Nubeqa® product sales & royalty ** Proprietary Products and Specialty Products *** Animal Health, Fermion and Contract Manufacturing **** Without Nubeqa® royalties Half-Year Financial Report 1-6/2021 © Orion Corpora
Slide 7: Development of operating profit in 1-6/2021 vs. 1-6/2020
Development of operating profit in 1-6/2021 vs. 1-6/2020 181 -10 -14 1 15 -29 146 3 * Product & service sales without sales margin and product mix change and exchange rate effect *** Exchange rate effect on gross margin ** Product sales margin and product mix change but without exchange rate effect
Slide 8: Geographical breakdown and development of net sales
Geographical breakdown and development of net sales 1-6/2021 MEUR 1-6/2021 1-6/2020 14% 250 29% -6% 9% -4% 200 191 181 150 152 158 -26% -6% 100 -6% 13% 95 35% 50 70 72 77 49 52 Finland Scandinavia 0 Other Europe North America RoW RoW = Rest of the World Half-Year Financial Report 1-6/2021 © Orion Co
Slide 9: Good development in business operations despite the decline in total net sales
Good development in business operations despite the decline in total net sales 1−6/2021 1−6/2020 1-6/2021 MEUR -2% -17% 7% 300 7% 244 249 243 250 202 39% 200 150 -4% -13% 100 47% 37 43 38 40 50 Proprietary Products 0 Specialty Products Specialty Proprietary Animal Fermion and Animal Health Products
Slide 10: TOP products in 1-6/2021
TOP 10 products in 1-6/2021 EUR million vs. 1-6/2020 1. Easyhaler® product portfolio 56 -9% 2. Stalevo®, Comtess®, Comtan® 52 -0% 3. Simdax® 29 -16% 4. dexdor® 20 -40% 5. Nubeqa® 19 +140% 6. Dexdomitor®, Domitor®, Domosedan®, Antisedan® 18 +18% 7. Divina® series 12 +14% 8. Burana® 11 -11% 9. Solomet
Slide 11: Proprietary Products
Proprietary Products 6 RION ing well-being Buildi
Slide 12: Expected sales development excluding the Easyhaler product family
Expected sales development excluding the Easyhaler® product family Proprietary Products MEUR -9% sales split 1-6/2021 70 -0% -51% 61 13% 60 56 26% 52 53 52 50 -16% -40% 10% 40 35 34 +140% 29 30 26 20 19 20 14% 8 10 27% 0 10% Easyhaler® Parkinson's Simdax® Dexdor® Nubeqa® Others portfolio franchise P
Slide 13: Nubeqa sales booked by Orion showing strong growth
Nubeqa® sales* booked by Orion showing strong growth 1-6/2021 Nubeqa® MEUR 19 (8) +140 % 15 10 MEUR 5 0 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2020 2021 * Orion’s sales to Bayer for commercial use + royalties from Bayer Half-Year Financial Report 1-6/2021 © Orion Corporation 19 July 2021 13
Slide 14: Easyhaler product portfolio sales -9%
Easyhaler® product portfolio sales -9% 1-6/2021 Budesonide-formoterol Easyhaler® MEUR 34 (37) -7% 40 1-6/2021 Other Easyhaler® products MEUR 21 (24) -12% 35 30 Sales, MEUR 25 20 15 10 5 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2017 2018 2019 2020 2021 Other Budesonide-formoterol
Slide 15: Sales of Parkinson's franchise at the previous year's level
Sales of Parkinson's franchise at the previous year's level 1-6/2021 Own sales MEUR 27 (24) +13% 40 35 1-6/2021 Deliveries to partners MEUR 25 (28) -11% 30 Sales, MEUR 25 20 15 10 5 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2017 2018 2019 2020 2021 Orion own sales Deliveries to p
Slide 16: Dexdor and Simdax - impact of generic competition starting to show
Dexdor® and Simdax® - impact of generic competition starting to show 1-6/2021 Dexdor® MEUR 20 (34) -40% 1-6/2021 Simdax® MEUR 29 (35) -16% 20 20 15 15 10 10 5 5 0 0 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 Half-Year Financial Report 1-6/2021 © Orion Corporation 19 July 2021 16
Slide 17: Specialty Products
Specialty Products
Slide 18: Good start for the year for Specialty Products even though net sales declined
Good start for the year for Specialty Products even though net sales declined from strong H1 2020 -5% MEUR Sales split 1-6/2021 160 140 133 139 14% 120 100 -11% 16% 80 +17% 60 42 38 40 34 34 34 54% 40 20 0 16% Finland Scandinavia Eastern RoW Europe & Finland Russia Scandinavia Eastern Europe & Russi
Slide 19: Good start for the year for Specialty Products even though net sales declined
Good start for the year for Specialty Products even though net sales declined from strong H1 2020 MEUR Sales split 1−6/2021 -2% 250 200 185 188 24% 150 -2% 100 60 61 50 0 76% Generic Self Care products prescription drugs Generic drugs Self-care products 1-6/2021 1−6/2020 Half-Year Financial Report 1
Slide 20: In Finland, Orion's reference priced prescription drugs developed better than the market
In Finland, Orion’s reference priced prescription drugs developed better than the market The market for reference priced prescription drugs in Finland* The sales of Orion's reference (1−6/2021) priced prescription drugs in Finland MEUR 215 (228) MEUR 51 (50) Market development Orion’s development -6
Slide 21: Orion is strong in home market Finland
Orion is strong in home market Finland Human pharma market in Finland 1-6/2021 Reference Self-care Medicinal and non-medicinal products priced products in hospital and pharmacy channels: EUR 1,421 million prescription Orion market share in MEUR drugs pharmacy 180 154 Orion market share in 160 140 ph
Slide 22: Research and development
Research and development
Slide 23: Key clinical development pipeline
Key clinical development pipeline Phase completed Phase ongoing Project/compound Indication Phase I Phase II Phase III Registration ARASENS / darolutamide 1 Prostate cancer (mHSPC) Phase I Phase II Phase III ARANOTE / darolutamide 1 Prostate cancer (mHSPC) Phase I Phase II Phase III ODM-208 Prostate
Slide 24: Key business targets in 2021
Key business targets in 2021 STATUS on TARGET 30 Jun 2021 Supporting sales growth and co-promotion in Europe with Bayer Positive outcome from Phase III ARASENS trial Taking phase III ARANOTE trial forward together with Bayer Sales growth ODM-208 Taking the development program forward according to pl
Slide 25: Corporate responsibility - targets and performance in 2020
Corporate responsibility – targets and performance in 2020 CORPORATE RESPONSIBILITY 2020 FOCUS AREA TARGET PERFORMANCE Ensuring availability of pharmaceutical products Patient safety and ensuring reliable supply of medications Ensuring patient safety Improving energy efficiency Environment Reducing
Slide 26: Outlook
Outlook ORION Building well-being
Slide 27: Outlook for 2021
Outlook for 2021 Net sales Orion estimates that in 2021 net sales will be slightly lower than in 2020 (net sales in 2020 were EUR 1,078 million). Operating profit Operating profit is estimated to be lower or clearly lower than in 2020 (in 2020 operating profit was EUR 280 million). Half-Year Financi
Slide 28: Key assumptions behind the outlook
Key assumptions behind the outlook Net sales Operating profit + Nubeqa® + Nubeqa® + Other growing products + No more depreciation expenses from Parkinson’s franchise - Milestones - Milestones - dexdor® - dexdor® - Simdax® - Simdax® - Animal Health - Normalisation of cost level (without Parkinson’s d
Slide 29: Upcoming events
Upcoming events Interim Report 1-9/2021 20/10/2021 Financial Statement Release for 2021 10/2/2022 AGM planned to be held 23/3/2022 Interim Report 1-3/2022 28/4/2022 Half-Year Financial Report 15/7/2022 Interim Report 1-9/2022 20/10/2022
Slide 30: Building well-being
Building well-being GRIoN Building well-being
Slide 31: Appendix
Appendix GRIoN Building well-being
Slide 32: Net sales and operating profit by quarter (MEUR)
Net sales and operating profit by quarter (MEUR) Net sales Operating profit 350 120 300 100 250 80 200 60 150 40 100 50 20 0 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 Half-Year Financial Report 1-6/2021 © Orion Corporation 19 July 2021 32
Slide 33: Quarterly net sales by unit (MEUR)
Quarterly net sales by unit (MEUR) Proprietary Products Specialty Products 150 150 100 100 50 50 0 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2017 2018 2019 2020 2021 2017 2018 2019 2020 2021 Animal Health Fermion & Contract Manufacturing 30 30 20 20 10 10 0 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2017 2018 2019 2020 2021 2017 20